Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director · Chief Executive Officer | September 19, 2026 | September 22, 2026 |
| Moelis & CoMC · Entity 3898 | Director | November 14, 2018 | November 16, 2018 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | June 08, 2022 | June 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date September 19, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,802 |
Reported balance
After 2026-09-19 transaction · row 1
1 source rowRow 1 · 2026-09-19 · Grant · Acquired 107 · Balance 95,802 F1: On February 23, 2016, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $50,000 to each employee who completes 10 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 10 years of continuous employment on September 19, 2026. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 407 |
Reported balance
Holding disclosure · report date 2026-09-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 407 F2: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 23, 2016, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $50,000 to each employee who completes 10 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 10 years of continuous employment on September 19, 2026.
F2: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
Moelis & Co
Report date November 14, 2018 · Filed November 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 2017 Annual Restricted Stock UnitsSEC Table I · non-derivative | Direct | 1,156.96 |
Reported balance
After 2018-11-14 transaction · row 1
1 source rowRow 1 · 2018-11-14 · Grant · Acquired 13.39 · Balance 1,156.96 F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F2: 2017 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2017. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. |
| 2018 Annual Restricted Stock UnitsSEC Table I · non-derivative | Direct | 706.23 |
Reported balance
After 2018-11-14 transaction · row 2
1 source rowRow 2 · 2018-11-14 · Grant · Acquired 8.17 · Balance 706.23 F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F3: 2018 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 2, 2018. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs. |
| 2018 Elective Restricted Stock UnitsSEC Table I · non-derivative | Direct | 1,059.34 |
Reported balance
After 2018-11-14 transaction · row 3
1 source rowRow 3 · 2018-11-14 · Grant · Acquired 12.26 · Balance 1,059.34 F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock. F4: 2018 Elective RSUs were issued as dividend equivalents on holder's underlying Elective RSUs issued on July 2, 2018. The dividend equivalent Elective RSUs will vest concurrently with the vesting of the underlying Elective RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Initial Restricted Stock Unit (RSU) represents the right to receive one share of Class A common stock.
F2: 2017 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2017. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs.
F3: 2018 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 2, 2018. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs.
F4: 2018 Elective RSUs were issued as dividend equivalents on holder's underlying Elective RSUs issued on July 2, 2018. The dividend equivalent Elective RSUs will vest concurrently with the vesting of the underlying Elective RSUs.
Pacira BioSciences, Inc.
Report date June 08, 2022 · Filed June 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,247 |
Reported balance
After 2022-06-08 transaction · row 1
1 source rowRow 1 · 2022-06-08 · Grant · Acquired 1,160 · Balance 13,247 F1: Represents restricted stock units that vest on June 3, 2023, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.39 · Expires 2032-06-08 | Direct | 8,225 |
Reported balance
After 2022-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-08 · Grant · Acquired 8,225 · Balance 8,225 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest on June 3, 2023, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2025 Filed Aug 19, 2025 21:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,646 | $452.96 | $745,572.16 |
DisclosureSEC source: 0001735276-25-000089 · edgardoc.xml · nonDerivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,201 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.49 to $453.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 514 | $451.99 | $232,322.86 |
DisclosureSEC source: 0001735276-25-000089 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,847 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.48 to $452.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 195 | $450.92 | $87,929.40 |
DisclosureSEC source: 0001735276-25-000089 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,361 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.42 to $451.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 450 | $449.92 | $202,464.00 |
DisclosureSEC source: 0001735276-25-000089 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,556 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.21 to $450.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 194 | $447.98 | $86,908.12 |
DisclosureSEC source: 0001735276-25-000089 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,006 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.53 to $448.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:27 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 14,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000089 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,200 F1 · kind: On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 12,080 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-25-000075 · edgardoc.xml · derivative · entry 12 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 839 Underlying: Common Stock · 12,080 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 12, 2024. F4 · derivative.exercise_date: This stock option was fully vested and exercisable as of December 1, 2021. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 7,217 | $0.00 Strike: $118.05 | $0.00 |
DisclosureSEC source: 0001735276-25-000075 · edgardoc.xml · derivative · entry 10 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 847 Underlying: Common Stock · 7,217 shares Expires 2030-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 12, 2024. F3 · derivative.exercise_date: This stock option was fully vested and exercisable as of February 26, 2024. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 19,297 | $306.00 | $5,904,882.00 |
DisclosureSEC source: 0001735276-25-000075 · edgardoc.xml · nonDerivative · entry 7 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,948 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 12, 2024. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 7,217 | $118.05 | $851,966.85 |
DisclosureSEC source: 0001735276-25-000075 · edgardoc.xml · nonDerivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 12, 2024. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 12,080 | $119.13 | $1,439,090.40 |
DisclosureSEC source: 0001735276-25-000075 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 12, 2024. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 12,081 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-25-000075 · edgardoc.xml · derivative · entry 11 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,919 Underlying: Common Stock · 12,081 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 12, 2024. F4 · derivative.exercise_date: This stock option was fully vested and exercisable as of December 1, 2021. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 19,559 | $0.00 Strike: $118.05 | $0.00 |
DisclosureSEC source: 0001735276-25-000075 · edgardoc.xml · derivative · entry 9 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,064 Underlying: Common Stock · 19,559 shares Expires 2030-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 12, 2024. F3 · derivative.exercise_date: This stock option was fully vested and exercisable as of February 26, 2024. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 6,171 | $306.00 | $1,888,326.00 |
DisclosureSEC source: 0001735276-25-000075 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,948 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 12, 2024. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 25,469 | $304.00 | $7,742,576.00 |
DisclosureSEC source: 0001735276-25-000075 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,119 F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 12, 2024. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 19,559 | $118.05 | $2,308,939.95 |
DisclosureSEC source: 0001735276-25-000075 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 12, 2024. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 12,081 | $119.13 | $1,439,209.53 |
DisclosureSEC source: 0001735276-25-000075 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 12, 2024. Read SEC document |
| May 16, 2025 Filed May 19, 2025 20:16 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GiftCommon Stock | 8,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000071 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,948 F1 · kind: The reported transaction involves a transfer of securities by bona fide gift for estate planning purposes to the Yvonne Greenstreet 2024 Irrevocable Trust Dtd 10/29/2024, of which the reporting person is neither the trustee nor a beneficiary. Read SEC document |
| May 02, 2025 Filed May 6, 2025 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GiftCommon Stock | 41,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000047 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,324 F1 · kind: The reported transaction involves a transfer of securities by bona fide gift for estate planning purposes to the Yvonne Greenstreet 2024 Irrevocable Trust Dtd 10/29/2024, of which the reporting person is neither the trustee nor a beneficiary. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 36,293 | $0.00 Strike: $243.53 | $0.00 |
DisclosureSEC source: 0001735276-25-000030 · edgardoc.xml · derivative · entry 10 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,293 Underlying: Common Stock · 36,293 shares Expires 2035-03-03 F11 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 4 | $248.36 | $993.44 |
DisclosureSEC source: 0001735276-25-000030 · edgardoc.xml · nonDerivative · entry 8 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,635 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 23 | $247.35 | $5,689.05 |
DisclosureSEC source: 0001735276-25-000030 · edgardoc.xml · nonDerivative · entry 7 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,639 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.04 to $247.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 238 | $246.18 | $58,590.84 |
DisclosureSEC source: 0001735276-25-000030 · edgardoc.xml · nonDerivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,662 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $246.00 to $246.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 580 | $245.26 | $142,250.80 |
DisclosureSEC source: 0001735276-25-000030 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,900 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $244.91 to $245.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 791 | $244.41 | $193,328.31 |
DisclosureSEC source: 0001735276-25-000030 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,480 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.90 to $244.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,173 | $243.36 | $285,461.28 |
DisclosureSEC source: 0001735276-25-000030 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,271 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.89 to $243.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,068 | $242.37 | $258,851.16 |
DisclosureSEC source: 0001735276-25-000030 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,444 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.87 to $242.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 17,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000030 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,512 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. F2 · balance_after: The Reporting Person has reported certain prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 17,965 newly awarded RSUs and 80,670 shares of common stock. The Reporting Person also holds 5,921 unvested RSUs that were previously reported in Table II. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:32 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 214 | $244.11 | $52,239.54 |
DisclosureSEC source: 0001735276-25-000023 · edgardoc.xml · nonDerivative · entry 9 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,547 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.90 to $244.32. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:32 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 440 | $243.23 | $107,021.20 |
DisclosureSEC source: 0001735276-25-000023 · edgardoc.xml · nonDerivative · entry 8 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,761 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.87 to $243.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:32 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,093 | $242.44 | $264,986.92 |
DisclosureSEC source: 0001735276-25-000023 · edgardoc.xml · nonDerivative · entry 7 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,201 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.86 to $242.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:32 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 461 | $241.51 | $111,336.11 |
DisclosureSEC source: 0001735276-25-000023 · edgardoc.xml · nonDerivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,294 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $240.85 to $241.85. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:32 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 284 | $240.32 | $68,250.88 |
DisclosureSEC source: 0001735276-25-000023 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,755 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $239.82 to $240.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:32 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 127 | $239.18 | $30,375.86 |
DisclosureSEC source: 0001735276-25-000023 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,039 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $238.73 to $239.69. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:32 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 123 | $238.33 | $29,314.59 |
DisclosureSEC source: 0001735276-25-000023 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,166 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $237.72 to $238.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:32 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 158 | $236.51 | $37,368.58 |
DisclosureSEC source: 0001735276-25-000023 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,289 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $236.50 to $237.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:32 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionRestricted Stock Units · Derivative | 5,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000023 · edgardoc.xml · derivative · entry 11 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,921 Underlying: Common Stock · 5,921 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. F12 · derivative.exercise_date: On February 27, 2023, the reporting person was granted 17,763 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2025, the second tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. F12 · derivative.expiration_date: On February 27, 2023, the reporting person was granted 17,763 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2025, the second tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:32 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 5,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000023 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 25 | $264.87 | $6,621.75 |
DisclosureSEC source: 0001735276-25-000012 · edgardoc.xml · nonDerivative · entry 13 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,526 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 21 | $263.33 | $5,529.93 |
DisclosureSEC source: 0001735276-25-000012 · edgardoc.xml · nonDerivative · entry 12 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,551 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 47 | $261.45 | $12,288.15 |
DisclosureSEC source: 0001735276-25-000012 · edgardoc.xml · nonDerivative · entry 11 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,572 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $261.42 to $261.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 38 | $260.57 | $9,901.66 |
DisclosureSEC source: 0001735276-25-000012 · edgardoc.xml · nonDerivative · entry 10 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,619 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $260.31 to $260.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 21 | $259.72 | $5,454.12 |
DisclosureSEC source: 0001735276-25-000012 · edgardoc.xml · nonDerivative · entry 9 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,657 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $259.21 to $260.14. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 59 | $258.07 | $15,226.13 |
DisclosureSEC source: 0001735276-25-000012 · edgardoc.xml · nonDerivative · entry 8 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,678 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $257.86 to $258.44. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 47 | $257.51 | $12,102.97 |
DisclosureSEC source: 0001735276-25-000012 · edgardoc.xml · nonDerivative · entry 7 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,737 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $257.05 to $257.78. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 98 | $256.29 | $25,116.42 |
DisclosureSEC source: 0001735276-25-000012 · edgardoc.xml · nonDerivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,784 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $256.01 to $256.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 85 | $255.56 | $21,722.60 |
DisclosureSEC source: 0001735276-25-000012 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,882 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $254.99 to $255.97. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 201 | $254.35 | $51,124.35 |
DisclosureSEC source: 0001735276-25-000012 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,967 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $253.96 to $254.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 300 | $253.37 | $76,011.00 |
DisclosureSEC source: 0001735276-25-000012 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,168 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $252.90 to $253.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 271 | $252.50 | $68,427.50 |
DisclosureSEC source: 0001735276-25-000012 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,468 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.89 to $252.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.